A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine [MVA 85A] Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2009
At a glance
- Drugs MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 10 Feb 2007 New trial record.